my tirzepatide is not working Why for Me? Common Causes Explained Why Am I Not Losing

The authors acknowledge the professional medical writing support from Clinical Communications, a division of MJH Life Sciences , Cranbury, NJ, which received funding support from Novo Nordisk Inc, Plainsboro, NJ

In people with type 1 diabetes, the pancreas does not produce insulin

Type 2 diabetes care requires in-person medical interventions not provided via telehealth, which is why Klinic does not prescribe Ozempic

Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas

Most common adverse events at all doses: Nausea (3355%, dose-related) Vomiting (1335%) Decreased appetite (1528%) Constipation or diarrhea (1020%) Injection-site reaction (510%) Dose-related dysesthesia signal: The TRIUMPH-4 trial identified a dose-related dysesthesia (nerve-tingling, paresthesia) signal: This is the most-flagged trial-level safety signal for retatrutide and the reason community doses cluster at 2-4 mg/week well below where the dysesthesia signal becomes prominent

At this stage, regular check-ins with your healthcare provider will help you stay on track, monitor your progress, and make any necessary adjustments to your treatment plan